Donepezil Hydrochloride Tablet, Film Coated
Product Images NDC 51407-320

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 51407-320). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

01 (30406488 Figure 01)

Chemical structure of Donepezil Hydrochloride showing the molecular arrangement including methoxy groups, piperidine ring, and benzyl group with the hydrochloride salt.*

FDA Label Image

Figure2 (30406488 Figure 02)

A line graph illustrating ADAS-cog change from baseline (mean ± SE) over weeks of drug treatment. It compares Donepezil Hydrochloride Tablets 10 mg/day, 5 mg/day, and placebo groups. The vertical axis denotes clinical improvement or decline, while the horizontal axis shows weeks up to 30. Data points for each treatment are plotted, showing trends in cognitive change over time.*

FDA Label Image

Figure-03 (30406488 Figure 03)

A cumulative percentage graph comparing patients' change from baseline on the ADAS-cog scale among three treatment groups: placebo, Donepezil Hydrochloride Tablets 5 mg/day, and 10 mg/day. The x-axis shows change from baseline (-15 to 15), and the y-axis shows cumulative percentage of patients (0-100%). A data table presents percentages of patients in each group with changes of -7, -4, and 0 points.*

FDA Label Image

Figure-04 (30406488 Figure 04)

A bar graph illustrating the CIBIC-plus rating distribution comparing Donepezil Hydrochloride Tablets at 10 mg/day and 5 mg/day doses versus placebo. The x-axis shows CIBIC-plus ratings ranging from Markedly Improved to Markedly Worse, and the y-axis represents the percentage of patients. Different colored bars represent each group.*

FDA Label Image

Figure-05 (30406488 Figure 05)

A line graph depicting the mean change from baseline in ADAS-cog scores over 12 weeks of drug treatment, comparing Donepezil Hydrochloride Tablets at 10 mg/day and 5 mg/day doses versus placebo. The y-axis shows clinical improvement and decline, while the x-axis shows weeks of treatment. Error bars represent standard errors.*

FDA Label Image

Figure-06 (30406488 Figure 06)

A cumulative percentage graph showing patients' change from baseline in ADAS-cog scores, comparing Placebo, Donepezil Hydrochloride Tablets 5 mg/day, and 10 mg/day. The x-axis represents change from baseline (-15 to 10), and the y-axis shows cumulative percentage of patients (0% to 100%). A table within the graph summarizes the percentage of patients achieving specific improvements (-7, -4, 0 points) across treatment groups.*

FDA Label Image

Figure-07 (30406488 Figure 07)

A bar graph showing the percentage of patients across different response categories (Markedly Improved, Moderately Improved, Minimally Improved, No Change, Minimally Worse, Moderately Worse, Markedly Worse) for three groups: Donepezil Hydrochloride Tablets 10 mg/day, 5 mg/day, and Placebo. The graph compares patient outcomes for these treatments.*

FDA Label Image

08 (30406488 Figure 08)

A line graph showing SIB (Severe Impairment Battery) change from baseline mean (±SE) over 0, 3, and 6 months of drug treatment. Two lines represent Donepezil Hydrochloride Tablets 10 mg/day (solid circles) and placebo (open squares). The Donepezil group shows clinical improvement, while the placebo group trends towards clinical decline.*

FDA Label Image

09 (30406488 Figure 09)

A cumulative percentage line graph comparing patients treated with Donepezil Hydrochloride Tablets 10 mg/day versus placebo. The x-axis represents SIB (Severe Impairment Battery) change from baseline, ranging from +30 to -75, and the y-axis shows the cumulative percentage of patients from 0 to 100%. Data points for Donepezil are shown as black circles and placebo as open squares, highlighting a distribution difference in patient responses.*

FDA Label Image

10 (30406488 Figure 10)

A line graph depicting the mean change from baseline in ADCS-ADL scores over 6 months of drug treatment comparing Donepezil Hydrochloride Tablets 10 mg/day versus placebo. The y-axis represents change from baseline, with positive values indicating clinical improvement and negative values indicating clinical decline. Data points at 0, 3, and 6 months show greater decline for the placebo group compared to the Donepezil group.*

FDA Label Image

11 (30406488 Figure 11)

A cumulative percentage curve comparing Donepezil Hydrochloride tablets 10 mg/day versus placebo. The x-axis shows ADCS-ADL change from baseline ranging from 20 to -20, and the y-axis shows the cumulative percentage of patients from 0 to 100%. The plot illustrates patient response distribution based on ADCS-ADL change.*

FDA Label Image

12 (30406488 Figure 12)

A line graph showing the SIB (Severe Impairment Battery) change from baseline over 24 weeks of treatment with Donepezil Hydrochloride Tablets at two dosage levels: 10 mg/day and 23 mg/day. The vertical axis represents the LS mean change with standard error, ranging from -3 to 5, indicating clinical decline below baseline and clinical improvement above baseline. The horizontal axis shows weeks of drug treatment at intervals of 0, 6, 12, 18, and 24 weeks. The 23 mg/day group shows greater SIB improvement compared to the 10 mg/day group throughout the treatment period.*

FDA Label Image

13 (30406488 Figure 13)

A cumulative percentage of patients chart comparing SIB (Severe Impairment Battery) change from baseline for Donepezil Hydrochloride Tablets 23 mg/day and 10 mg/day. The x-axis shows SIB change from baseline with negative and positive values, while the y-axis shows cumulative percentage of patients from 0 to 100%. The chart uses diamond symbols for 23 mg/day and circles for 10 mg/day dosing.*

FDA Label Image

14 (30406488 Figure 14)

A bar chart comparing the percentage of patients across different CIBIC-plus Ratings for Donepezil Hydrochloride tablets at 23 mg/day and 10 mg/day dosages. The x-axis represents CIBIC-plus Ratings categories from Markedly Improved to Markedly Worse, and the y-axis shows the percentage of patients, highlighting patient response distribution by dosage.*

FDA Label Image

15 (30406488 Figure 15)

FDA Label Image

51407-320-30ol.jpg (51407 320 30ol)

Donepezil Hydrochloride 23 mg film-coated tablets packaging label showing 30 tablets per bottle. The label includes the NDC 51407-320-30, manufacturer Golden State Medical Supply, Inc., and storage instructions. The text is primarily in purple and black with a barcode and an Rx only designation.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.